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ABSTRACT
Targeted cancer therapeutics are promised to have a major impact on cancer 
treatment and survival. Successful application of these novel treatments requires a 
molecular definition of a patient’s disease typically achieved through the use of tissue 
biopsies. Alternatively, allowing longitudinal monitoring, biomarkers derived from 
blood, isolated either from circulating tumor cell derived DNA (ctcDNA) or circulating 
cell-free tumor DNA (ccfDNA) may be evaluated. In order to use blood derived 
templates for mutational profiling in clinical decisions, it is essential to understand 
the different template qualities and how they compare to biopsy derived template DNA 
as both blood-based templates are rare and distinct from the gold-standard. Using 
a next generation re-sequencing strategy, concordance of the mutational spectrum 
was evaluated in 32 patient-matched ctcDNA and ccfDNA templates with comparison 
to tissue biopsy derived DNA template. Different CTC antibody capture systems for 
DNA isolation from patient blood samples were also compared. Significant overlap 
was observed between ctcDNA, ccfDNA and tissue derived templates. Interestingly, 
if the results of ctcDNA and ccfDNA template sequencing were combined, productive 
samples showed similar detection frequency (56% vs 58%), were temporally 
flexible, and were complementary both to each other and the gold standard. These 
observations justify the use of a multiple template approach to the liquid biopsy, 
where germline, ctcDNA, and ccfDNA templates are employed for clinical diagnostic 
purposes and open a path to comprehensive blood derived biomarker access.
INTRODUCTION
Cancer remains one of the leading causes 
of morbidity worldwide. Treatment decisions and 
response monitoring is historically dependent on serial 
imaging technologies and disease-specific pathologic 
characterization of tissue biopsies typically obtained at time 
of primary surgery. This generic and standard approach 
does not support effective cures in the advanced setting 
primarily because of the inability of cytotoxic therapy to 
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deal with tumor heterogeneity. In the last few years, the 
emergence of next generation sequencing tools has cast a 
very different light on the nature of tumor clonality with 
the ability to build an emerging model describing a much 
more heterogeneous disease than previously understood [1, 
2]. This raises problems in determining the best diagnostic 
approach when dealing with a disease characterized 
by a dynamic plasticity that could be not captured in its 
complexity by the simple molecular snapshot offered 
by a one-time tissue biopsy. The traditional biopsy is 
increasingly understood as too restrictive to monitor 
relevant changes in progression and resistance because it 
represents a “geographically” and “temporally” restricted 
sample with implications in patients’ management [3]. 
This has driven the development of various “liquid biopsy” 
technologies that seek to address the need for monitoring 
tools that use the specific readout of DNA based biomarkers 
to monitor changes in tumor profile [4].
The earliest version of a liquid biopsy was built 
on careful enumeration of a small number of cells that 
could be found in the blood of patients with epithelial 
cancers [5, 6]. In the most mature form, this resulted in 
the FDA approved CellSearch™ test. Using EpCAM to 
recover, and intracellular expression of Cytokeratin to 
detect a population of cells, it was shown this population 
of circulating epithelial cells predict worse outcome, 
faster disease progression, and increased likelihood 
of metastatic events [7]. This population came to be 
known as circulating tumor cells (CTC). However there 
were several problems demonstrated with the approach. 
Molecular evaluation has shown some but not all of the 
cells bear molecular hallmarks of cancer [8-10]. Also, 
this restricted phenotypic definition of a tumor cell was 
described prognostically and so excluded many classes of 
informative cells [11-14]. As a result, CTC enumeration 
using these legacy definitions frequently returns limited 
or absent numbers of cells. Maybe most importantly, CTC 
counting has been ineffective at demonstrating clinical 
utility in the advanced setting for individual patients [15]. 
Despite those limitations, because of their detection in a 
peripheral blood sample, circulating tumor cells provide 
an attractive source of genetic material for longitudinal 
monitoring in view of the minimal invasiveness of a blood 
draw and their potential to reflect the molecular profile of 
the metastatic cell population [8, 16-17].
Circulating cell-free DNA was identified in 1948 
in the plasma and derives from both normal and diseased 
tissue [18]. Clinical studies have shown ccfDNA can 
act as a suitable template for cancer monitoring and 
management [19-22]. Unlike circulating tumor cells, 
studies suggest ccfDNA representation aligns with 
disease burden and disease type [23]. As such, the reasons 
ctcDNA and ccfDNA are found in blood are different 
with CTC representing the mobile cellular aspect of a 
tumor while ccfDNA is produced chiefly as a product of 
apoptosis [24, 25].
In summary, two primary sources of DNA template 
are available from cancer patient blood samples. These 
templates have been interrogated for specific known 
mutations using ultra sensitive PCR based techniques 
[26]. However the mutational spectrum from these two 
sample types have never been compared because of the 
signal to noise challenge for enriching rare tumor cells 
and a clear comparison of template quality has never been 
performed. Furthermore, there has not been a concordance 
study between ctcDNA, ccfDNA, and formalin fixed, 
paraffin embedded tissue (FFPE) from the same patient 
and blood draw using sequencing. One reason for this 
has been technical. Previous studies to compare the 
two templates have reached different conclusions based 
on technical limitations for enrichment techniques or 
based on evaluation with molecular tools that are not 
directly comparable [21]. Recent advances in separation 
technologies have provided a solution for this technical 
problem [27]. The LiquidBiopsy® platform (Cynvenio 
Biosystems), allows for isolation of useful amounts of 
ccfDNA and ctcDNA from the same patient blood draw. 
Typically the amount of ccfDNA and ctcDNA recovered 
per blood draw is sufficient to produce patient matched 
NGS libraries. The use of NGS means tumor cells and 
tumor derived DNA fragments can be defined as mutation 
bearing events and can therefore be directly compared. In 
this report we describe a generalizable strategy using NGS 
on 32 matched FFPE, ccfDNA and ctcDNA samples from 
clinical samples.
RESULTS
Characterization of clinical samples
In this study, patients were recruited based on a 
confirmed diagnosis of metastatic breast cancer. The 
samples were collected at baseline, either before start of 
a new therapy or at completion of staging diagnosis. A 
tissue biopsy specimen of the metastatic recurrence was 
mandatory. The patients were predominantly female (97%) 
and all had stage IV disease. The remaining characteristics 
are shown in Table 1. Formalin-fixed, paraffin-embedded 
(FFPE) tumor specimens were obtained for all patients 
for whom sufficient tissue remained in the pathology 
block of the metastatic lesion. Of 32 patients, 7 had either 
insufficient DNA recovered for sequencing, too little or 
no tumor component to the biopsy or no remaining biopsy 
tissue. 25 of 32 samples were successfully evaluated.
Target recovery and extraction of ctcDNA and 
ccfDNA template
EpCAM is the legacy marker for recovery of CTC 
in breast cancer. To expand the definition of cells that 
can be functionally recovered, a cocktail of antibodies 
that recognize surface receptors in addition to EpCAM 
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were evaluated. Tumor cells representing the five 
major subtypes of breast cancer were added to 7.5mL 
normal healthy blood samples and recovered using the 
LiquidBiopsy system (Figure 1). The five subtypes; 
Basal, Claudin low, Her2, Luminal A and Luminal B, 
were each represented by two different well characterized 
tumor cell lines [28]. The efficiency of recovery using 
EpCAM was compared to capture with EpCAM, Her2, 
and Trop2 (an epithelial/mesenchymal transition profile 
(EMT)). Recovery (top graph) and purity (bottom graph) 
of samples engineered with 90c/mL of each cell line 
were determined. The same cell lines were evaluated by 
Table 1: Characteristics of normal and metastatic cancer samples analyzed for peripheral templates
Characteristic Number Range (%)
Normal Controls
Number
total Normals 31
Age (years)
Median 48 30-74
Sex
Male 13 (42%)
Female 15 (48%)
Unknown 3 (10%)
Metastatic Cancer Samples
Number
Total 32
Age (years)
Median 55 36-82
Sex
Male 1 (3%)
Female 31 (97%)
BC subtype
Luminal A 15 (47%)
Luminal B 6 (19%)
Her2 4 (13%)
TNBC 6 (19%)
Unknown 1 (3%)
Pathologic stage
Stage IV 31 (97%)
Unknown 1 (3%)
No. of lines of Therapy
Median 4 0-13
Sampling Interval
Synchronous (≤6 months) 17 0-18 weeks (53%)
Asynchronous (≥6 months) 14 31-240 weeks (44%)
Not available 3 (3%)
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FACs for expression of the three markers. EpCAM only 
based recovery gave between <1% and 103% recovery 
of engineered samples. Consistent with patterns of 
expression, Claudin low and Basal type breast cancer 
cell lines demonstrated the least recovery with EpCAM 
alone. Addition of Her2 and Trop2 specific antibodies 
incremented recovery of target cells when those receptors 
were expressed. So HCC-1569, MDA-MD-231 and HCC-
1937 cell recovery was significantly improved by the pool 
of antibodies. There is a consistent inhibition of capture 
of MCF7 cells when the mixture of antibodies is used 
possibly due to stearic hinderance. Despite this, when 
a receptor is available for capture, the 90c/mL samples 
were recovered with an average efficiency of 77% using 
the EMT cocktail. Critically, with the exception of HCC-
1395 which demonstrated no significant capture with 
either reagent set, 90 tumor cells/mL could be enriched 
to an average purity of between 29% and 67% from 
whole blood (see bottom graph). Thus, the LiquidBiopsy 
platform could reproducibly enrich target cells on the 
order of 105-106 fold enrichment.
Applying this approach to clinical samples, tumor 
cell populations were enriched using EpCAM targeted 
capture and compared to EMT targeted capture. This 
Figure 1: Tumor cells representing the five major subtypes of breast cancer were recovered from 7.5mL blood samples 
using the LiquidBiopsy system. The efficiency of recovery using EpCAM compared to capture with EpCAM, Her2, and Trop2 (top 
graph) and purity (bottom graph) are shown. Each sample was evaluated in quadruplicate and the bars represent means (+ 1 SD) The same 
cell lines were evaluated by FACs for control IgG1 (purple), EpCAM (blue), Trop2 (red) or Her2 expression (green) as detected using 
Streptavidin-FITC.
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enrichment protocol was applied to 32 serial patient 
samples from metastatic breast cancer who were otherwise 
not selected for elevated CTC numbers. EpCAM based 
enrichment served as a control and was compared to 
cell populations selected with EMT cocktail. 32 blood 
samples were processed for EpCAM only with an average 
recovered purity of 7.7% Cytokeratin positive (CK+) cells. 
By comparison, EMT selection enriched populations with 
on average 8.8% cytokeratin positive cell populations with 
a larger range of cells than EpCAM selected (see Table 2). 
Importantly, the median number of CK+ cells recovered 
from EMT capture was almost three times elevated 
over EpCAM alone. (median of 23.5 cells/7.5mL vs 8.0 
cells/7.5mL for EMT and EpCAM respectively). Also, the 
median number of CD45+ non-target cells captured was 
116 and 172 cells respectively. This background is relevant 
to a sequencing test that supports detection of mutations 
present at >1%. ccfDNA sample was purified from the 
same tube of blood. The average concentration of ccfDNA 
recovered from fixed plasma samples was 7.3 ng/mL.
Evaluation of template quality
Interpreting NGS data rests on a clear understanding 
of the quality of template that is being interrogated. A 
sequencing pipeline was designed supporting case control 
detection of single point variants to 1% (Supplementary 
Figure S1). A primary distinguishing feature between 
ccfDNA and ctcDNA is the fragmented nature of the 
ccfDNA that has been described and observed previously 
[29, 30]. For the purposes of this experiment, the variance 
of amplification efficiency manifest in the ccfDNA 
demonstrated that approximately half of the amplicons in 
ccfDNA amplified the target sequence less efficiently than 
control (Supplementary Figure S2). To ensure sufficient 
coverage of the fragmented template, we therefore 
decided to devote one 318 chip to the analysis of each 
ccfDNA sample.
A second characteristic distinguishing ccfDNA 
and cell based DNA sequence came from the evaluation 
of the SNV substitution frequency (SNV-SF). The SNV-
SF results in a quality metric that can be used to evaluate 
accuracy and precision as well as process-associated or 
biologically-associated noise and was used as a general 
metric for mutation frequency. To evaluate SNV-SF, 
template from the different compartments recovered 
from a single sample were evaluated using the AmpliSeq 
hotspot panel. After alignment, the template specific 
libraries were compared to germline sequence and only 
alterations with >2000 reads were evaluated. However, 
the reportable range for SNV-SF determination was not 
restricted to the Cosmic identified SNV in the Hotspot 
library. Therefore, any alteration detected that could not 
be eliminated by comparison to germline was included. 
This general calculation gives a comparison of different 
sample types from the same patient.
The SNV-SF was calculated on ccfDNA and 
circulating cell DNA recovered from 29 normal healthy 
volunteers. This analysis revealed a three-fold difference 
in the number of alterations observed in a known negative 
sample set (Figure 2). Thus, there is a noise variable 
manifest in ccfDNA as altered sequence that is based on 
the compartment of the DNA template rather than the 
sequencing reaction or the sequencing platform. A two-
tailed Wilcoxon rank sum test measured a p value of 
0.0009. If we assume that all SNVs detected in healthy 
donors are false positives then there is a 3-fold higher 
noise in the ccfDNA samples compared to the matched 
circulating cell DNA sample. This difference is detected 
on template fixed in the same sample tube, for the same 
time and measured with the same test. It therefore suggests 
the noise variable in ccfDNA is a biological noise rather 
than a system or assay noise. As a result, the primary 
comparison of ccfDNA and ctcDNA was restricted to 
the panel of COSMIC validated SNVs mapping to the 
AmpliSeq Hotspot panel in the CLIA validated test. These 
restrictions allowed de novo identification of template 
associated mutations across >2500 different mutations and 
therefore represents a toolset and workflow that supports 
mutation discovery on multiple templates from a single 
blood draw.
Clinical sequence output: Primary comparison 
of different templates
An important measure for clinical relevance of a 
NGS test is the detection of disease associated alterations 
in templates derived from tumor sample. This experiment 
was conducted on a cohort of metastatic breast cancer 
samples. After assembly, all variants were filtered to 
yield COSMIC validated mutations. For cell enrichment, 
we initially included EpCAM based recovery to compare 
capture to a cocktail of EpCAM/Her2/Trop2. As shown 
in Supplementary Table S1, the frequency with which 
EpCAM capture alone supported identification of 
mutation bearing cells was 9%. The EMT cocktail 
outperformed the EpCAM only capture by 3-fold (Table 
3). Therefore, these data focus on characterizing the 
EMT performance.
The ctcDNA and ccfDNA samples were analyzed 
using a case-control model with a limit of detection of 
1%. For FFPE, no case-control was used and the limit 
of detection was 10%. The incidence for detection of 
variants in evaluable FFPE samples using the AmpliSeq 
panel was 54% (14 of 26 with 6 samples QNS). The 
genes most frequently mutated were TP53 and PIK3CA 
with mutation frequencies of 20 and 28% respectively. 
This is consistent with these being the most frequently 
altered genes in breast cancer. The frequency of mutations 
observed in ccfDNA and EMT ctcDNA samples was 
48% and 25% respectively. Similar to the FFPE analysis, 
the most frequently altered genes were again TP53 and 
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PIK3CA. Specifically, mutations in TP53 and PIK3CA 
were detected with 16% and 9% frequency respectively in 
the ctcDNA from 32 evaluated samples. Mutations in the 
same genes were observed with 29% and 16% frequency 
in ccfDNA. In combination, ccfDNA and EMT ctcDNA 
produced SNV information 56% of the time - a frequency 
directly comparable to the FFPE sample frequency of 
58%. Therefore overall, the peripheral multitemplate 
analysis produces signal with 98% of the frequency of 
evaluable FFPE samples.
The impact of sampling on heterogeneity can 
be observed both within a sample type as between 
compartments. For instance, sample CYN-026 described a 
TP53 (C182Y) mutation in a bone marrow derived biopsy 
sample. A synchronous bone marrow sample displayed 
a distinct TP53 alteration (G108S) as well as alterations 
in APC (G1447*) and PIK3CA (H1047R). The PIK3CA 
alteration but neither of the TP53 or the APC alterations 
were detected in the peripheral samples. Furthermore, the 
PIK3CA alteration was detected in the EMT population 
Table 2: Target cell recovery performance
CK+ cells/7.5mL CK+ purity 
(%CK+)
CD45+/ 
DAPI+/7.5mL
Capture Cocktail Median sd Average Range Median
EpCAM 8.0 20.3 7.7% 1 - 112 116
EpCAM/Her2/Trop2 23.5 88.4 8.8% 2 - 487 172
Figure 2: Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF 
Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donors. 
Paired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample. Alterations with an 
extended reportable range to include all evaluated bases in the library were enumerated. A two-tailed Wilcoxon rank sum test measured a 
mean difference of 3.0 and a p value of 0.0009.
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Table 3: COSMIC identified SNV from matched tumor samples derived from blood or biopsy 
ID E/P/H ctcDNA ccfDNA FFPE 1 FFPE 2
C293-001 +/+/- X X X
C293-002 -/-/+ TP53; p.E285K X QNS tissue
C293-003 -/-/+ X X X
C293-004 +/-/- X PIK3CA;p.E542K PIK3CA;p.E542K PIK3CA;p.E542K
C293-005 +/-/+ X PIK3CA; p.V344G PIK3CA; p.V344G
ERBB2; p.V777L ERBB2; p.V777L
C293-006 -/-/- X TP53;p.H193R TP53;p.H193R
C293-007 -/-/- X X KRAS; V14I
C293-008 NA X TP53; p.S215R QNS tissue
C293-009 +/+/Eq X X X
C293-010 +/-/+ TP53; p.Y163D TP53; p.Y163D QNS Tissue
C293-011 -/-/- X TP53; p.R175H TP53; p.R175H
C293-012 +/-/- X X X
C293-013 +/+/- X QNS DNA PIK3CA; p.H1047R X
C293-014 +/+/Eq X TP53; p.M246I X
C293-015 -/-/- X X X
C293-016 -/-/+ PIK3CA; p.E545K X QNS Tissue
C293-018 +/-/-
PIK3CA; 
p.H1047R
PIK3CA; p.H1047R QNS DNA
PIK3CA; 
p.H1047R
C293-019 +/+/- X X IDH2; p.R140Q
C293-020 -/-/- X X X
C293-021 +/+/- X GNAQ; Q209K X
C293-022 +/+/- X X PIK3CA; p.E545K
C293-023 -/+/Eq TP53; p.R175H TP53; p.R175H TP53; p.R175H
C293-024 +/-/- X PIK3CA; p.H1047R X PIK3CA; 
p.H1047R
C293-025 +/-/- X X X
C293-026 +/-/Eq
PIK3CA; 
p.H1047R
PIK3CA; p.H1047R TP53; p.C182Y APC; p.Q1447*
TP53; p.G108S
PIK3CA; 
p.H1047R
C293-027 +/+/- TP53; p.H178P X X
C293-028 +/-/- X X QNS DNA
C293-029 -/-/+ X TP53; p.E286K QNS DNA
C293-030 +/+/- X X ERBB2; V777L
C293-031 +/+/- X X X
(Continued )
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but not the epithelial population. In another sample 
(CYN-003) a mutation in PIK3CA (E542K) is detected 
in two biopsy samples and the ccfDNA compartment but 
is not detected in either the epithelial or EMT cells. In 
contrast, CYN-016 identifies a PIK3KCA (E545K) driver 
mutation in EMT cells that is not detected in ccfDNA. 
The biopsy sample for the latter subject had insufficient 
tumor tissue on pathology review for sequence analysis. 
Thus, whether sampling different biopsy sites or different 
peripheral compartments, the three different templates are 
complementary.
Evaluating the impact of different tumor sampling 
mechanisms has been challenging due to limited studies 
capable of making direct comparisons between samples 
and indexing the template quality and performance on 
different templates but with the same assay. Due to the 
impact of insufficient biopsy material (QNS), mutations 
were described in 47% of the FFPE samples (26 evaluable 
samples of 32 subjects). Of that number, 9 samples (28%) 
produced peripheral signal from either ccfDNA or ctcDNA 
or both that was concordant with FFPE. Separately, 
while 72% of the samples have some information in one 
compartment or the other, 44% (10 of 23 samples) of any 
alteration could be confirmed in an orthogonal template 
(Table 3).
The relationship between the different sampling 
mechanisms is described in Figure 3. The orthogonal 
nature of the three sampling mechanisms detected is 
impacted both by the different source of sample as 
well as the chance that no tumor derived material is 
detected in either FFPE or the peripheral samples. The 
overlap of SNV mutation calls between sample types 
(FFPE, ctcDNA, ccfDNA) was compared. Concordant 
results were measured as the presence of any specific 
mutation between different sample types in the same 
patient. There were clinically relevant and potentially 
actionable mutations detected in EMT ctcDNA samples 
or ccfDNA samples that were not shared with other 
sample types. Thus EMT ccfDNA and ccfDNA produce 
complementary data that can supplement rare signals 
in either compartment or can serve as orthogonal 
confirmatory templates. Furthermore, the ability to tune 
the informative cell population can dramatically alter the 
frequency of informative reads.
DISCUSSION
In this prospective study, we compared NGS data 
sets from three distinct patient-matched samples types 
(FFPE, ctcDNA, ccfDNA). A common amplicon based 
resequencing panel (Ampliseq v2 HotSpot panel) was 
used for all template types in a NGS pipeline using 
identical variant analysis. Patients with available quality 
tissue specimen from diagnostic biopsy were isolated and 
compared. We demonstrated that ccfDNA and ctcDNA 
evaluation yields complementary molecular information 
from the same blood sample. Moreover, the capture of 
CTC for molecular analysis may be tuned based on a 
molecular detection system. In fact, the capture protocol 
for circulating mutation bearing cells was a novel cocktail 
of anti-EpCAM, Her2, and Trop2 antibodies. This cocktail 
was designed based on the established role of EpCAM in 
defining a population of cells in blood that is prognostically 
related to disease progression as well as metastatic events 
[31, 32]. The additional markers have established an 
emerging utility for antibody directed therapies in breast 
cancer targeting Her2 and Trop2 respectively [33-36]. 
While other cocktails have been tested, only a subset 
has been shown to be productive for the detection of 
mutation bearing cells [11, 37]. Furthermore, in our study 
the detection and molecular analysis of CTCs was not 
dependent on clinical or biological outcome to interpret 
the value of the populations. Specifically, the CellSearch 
test is not dependent only on EpCAM expression per se. 
Rather, if anything changes, including cells or reagents, the 
approved prognostic value is lost. For these applications, 
the most important result is the demonstration that the 
informative template from a blood sample may now be 
defined molecularly as related to the disease process by 
orthogonal characterization of DNA alterations. DNA 
based analysis of SNV was utilized to demonstrate 
qualitative characteristics between the different template 
compartments. Having validated the capture definition, 
the informative cell population may now be interrogated 
for additional biomarkers of value such as expression of 
protein markers [38], protein modification events, or RNA 
expression based analysis for biomarkers that are opaque 
in the DNA compartment such as the AR-V7 splice variant 
in prostate cancer [39].
ID E/P/H ctcDNA ccfDNA FFPE 1 FFPE 2
C293-032 -/-/- X TP53; p.Y107* X
C293-033 +/+/- TP53; p.C176F TP53; p.C176F TP53; p.C176F
TP53; p.C176S
Most recent hormonal (ER/PR) and Her2 status is included where available (E/P/H) and indicated as present (+), absent 
(-), or equivocal (Eq). Alterations are indicated by the target gene and the predicted impact. Samples with no detectable 
alteration at the limit of detection are indicated by X. Samples that were quantity not sufficient (QNS) are indicated.
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The additional goal of these comparisons was to 
evaluate different template compartments for the ability 
to provide clinically useful DNA sequence information. 
The measures of success for these comparisons were 
deemed to be i) the frequency of disease associated 
alterations observed in the analysis of multiple 
templates (tissue, ctcDNA or ccfDNA) and ii) the 
quality of template for supporting sequence analysis. 
A key observation is that the FFPE sample and the 
complementary peripheral samples together provide 
molecular information in a similar proportion of samples. 
In these data, all templates are detecting alterations 
within a two-fold range of each other. Previous studies 
comparing CTC and ccfDNA have been limited by 
making comparisons with different technologies [21] 
or using shared readouts that do not alter the significant 
signal to noise challenge of detecting rare mutation 
bearing cells [23]. These approaches made it challenging 
to perform a direct comparison of ccfDNA and ctcDNA. 
A recent report demonstrating the presence of a T790M 
resistance mutation in lung cancer supports the data 
presented here in that ctcDNA and ccfDNA produce 
complementary information [26].
Fundamental to this experiment is the ability to 
clarify the population of cells molecularly. There are 
numerous approaches to recovering tumor cells from 
blood samples ranging from size based selection, to 
mechanical mechanisms, charge based approaches or 
no selection. Each has applications for discovery of 
previously uncharacterized cell populations. In a patient 
setting, population based (as opposed to single cell) 
analysis of cells or ccfDNA fragments allows more rapid 
molecular analysis but also uses a sampling mechanism 
that may be less sensitive to analytic variables. A 
significant advantage of positive selection approaches is 
the ability to standardize the enrichment definition around 
a standardizable biological definition.
The studies reported here are based upon the 
examination of cell pools, as well as mixtures of 
ccfDNA isolated from whole blood. To the best of our 
knowledge, there are no published data that show a 
population of tumor cells in blood can be productively 
recovered and sequenced directly yielding a clinically 
relevant mutational spectrum. Other direct evidence 
for the significant presence of mutation bearing cells 
has come from single cell experiments or single cell 
Figure 3: COSMIC identified SNV from matched tumor samples derived from blood or biopsy. Alterations are counted in 
all clinical samples. Overlap between each template is depicted by Venn diagram with comparison between FFPE, ccfDNA and ctcDNA 
compartments.
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based readouts such as FISH analysis [10, 40-42]. 
Despite that, a number of studies demonstrated the 
presence of cells in blood that contain mutations that 
can be tracked back to the tumor but almost all are 
restricted single cell selection [43], single cell analysis 
[44, 45], or single cell propagation steps [11, 37]. The 
population based approach we present in this paper 
supports high throughput based analysis. In addition, 
a median background of 172 CD45+ events from a 
7.5mL blood sample will allow detection of as few as 
3-4 heterozygous events from a blood sample using a 
test that can detect mutations with a 1% frequency; a 
performance already approaching a single cell detection 
event. Furthermore, individuals without cancer exhibit 
recoverable cells with a phenotype related to circulating 
epithelial cells [46, 47]. However these cells do not bear 
cancerous SNV mutations. It will be important therefore 
to develop advanced validation tools, like detection of 
DNA alterations, before further characterization of cell 
populations with tools such as expression profiling. 
Even enumeration has to be indexed to a clinically 
prognostic impact or molecular demonstration that the 
cell population is truly tumor derived.
The current data demonstrate that both blood 
derived templates support informative amplicon based 
resequencing. However, significant differences between 
the templates with respect to their performance in NGS 
variant analysis suggest that the templates need to be 
handled according to their strengths and weaknesses 
by standardizing the analysis rules. Key among these 
observations was the demonstration of a variant noise 
detected in the ccfDNA that is significantly elevated 
over cell based analysis from the same sample. This 
noise was detected at random sites within the amplicon 
that are not associated with the disease process 
and need to be eliminated by a restriction call using 
bioinformatic methods. This has implications for the 
ability to use this approach to map de novo mutations 
discovered in the ccfDNA template. One hypothesis 
to explain this noise, postulates that noise is due to 
the fixative or preservative utilized, analogous to 
the template damage observed with FFPE template 
[48]. However the absence of a similar noise profile 
in other matched DNA templates recovered from the 
same sample argues against this hypothesis. ccfDNA 
is a degradative product of catabolism, present in the 
extracellular compartment and therefore is susceptible 
to multiple processes of damage in plasma. Indeed, 
when specifically evaluated, a similar background has 
been described elsewhere [49]. Alternatively, given the 
data suggesting accumulation of DNA damage over 
time in preneoplastic tissues, we can speculate that this 
template associated noise might be a reflection of that 
larger phenomenon in biology, in essence detecting a 
level of “normal” DNA damage even in the absence 
of diagnosed malignancies with potential implications 
for future studies [50-52]. Certainly, this difference 
between ctcDNA and ccfDNA quality reflects the 
known differences in their biological source and has 
implications for the prognostic value of each biomarker 
[53].
Clearly, detection of tumor related events depend 
on the targets included in the NGS test. The AmpliSeq 
v2 Hotspot panel is a well curated pan-cancer panel that 
has been shown to identify disease associated alterations 
in FFPE and ccfDNA [54-56]. The most frequently 
mutated alterations in breast cancer are detected with 
related frequencies in the multiple templates. However, 
not all disease associated mutations can be included in 
any targeted panel. More comprehensive whole genome 
or whole exome sequencing is possible but should be 
considered in the context of the enzymatic amplification 
steps necessary to produce sufficient template from 
limiting numbers of cells and the impact on sequence 
integrity. Therefore, it will be key to develop detection 
tools that reflect the most relevant decision points for 
any given patient population. For instance, in breast 
cancer, there are clinically relevant biomarker targets 
in the protein, RNA or DNA compartments [57-63]. 
Functional access to both ccfDNA and CTC based 
templates supports development of protein and RNA 
based readouts in addition to detection of DNA based 
alterations.
This study demonstrates that it is possible to 
productively interrogate both populations of mutation 
bearing cells enriched from a blood sample and 
ccfDNA. Importantly, this analysis does not require 
a priori knowledge of the mutations present and 
will serve as a useful discovery tool. Expanding the 
definition of informative cell populations may now be 
indexed to a molecular definition. This ability to define 
populations beyond the legacy epithelial definition 
raises the possibility of informative biomarkers in 
non-epithelial settings such as soft tissue cancers, 
skin cancers such as melanoma, or epithelial cancers 
that have not previously performed well with strictly 
epithelial markers but still characterized by metastatic 
events.
Fundamentally, tumor derived samples from biopsy, 
circulating tumor cell populations and ccfDNA are 
acquired by different sampling mechanisms; mechanisms 
that capture different moments of the disease and 
potentially not necessarily the same biological sources. 
The study of these alternate templates by next generation 
sequencing technologies has emphasized the clonal nature 
of cancer and the impact of evaluating these different 
biopsy sites [64]. The emerging model for the peripheral 
templates suggest ccfDNA samples the genomic DNA 
fragments released from all tumor sites. In contrast, 
circulating tumor cells are clearly related to the disease 
process, predict more aggressive disease and increased 
metastasis [65]. As such, CTC reflect the mobile and 
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metastatic subset of tumor cells. Clearly the overlap 
between detectable alterations in each compartment 
demonstrates the relevant information may not always 
be linked to one specific compartment or one biology. An 
ability to evaluate multiple compartments, both in terms 
of sensitivity and biomarker definition, is an innovative 
approach that can have significant impact with regards 
to diagnosis and on our capacity to better understand 
the various biological processes driving metastases and 
potentially different therapeutic approaches. The impact 
of these biological differences will have to be determined 
in prospective studies.
MATERIALS AND METHODS
Ethics statement
This prospective clinical trial was funded with a 
NIH/NCI contract with the express purpose of expanding 
the definition of evaluable tumor cells in blood. The long 
term goal of the SBIR contract was to develop new devices 
and methods of CTC detection with a focus on clinical 
tools rather than research based approaches. Patients were 
enrolled at three different sites (Kimmel Cancer Center of 
Thomas Jefferson University, Winship Cancer Institute of 
Emory University, and The West Clinic). Normal human 
donor blood was purchased from HemaCare Corporation. 
All subjects provided written informed consent under an 
Institutional Review Board approved protocols.
Study subjects
The study was designed to enroll subjects with a 
confirmed diagnosis of metastatic breast cancer that were 
about to start a new line of therapy for their disease. A 
tissue biopsy of the metastatic lesion was mandatory. 
After appropriate consent enrolled subjects provided a 
blood sample before starting the new therapy. The blood 
samples had a minimum volume of 16mL minimum from 
two K2-EDTA tubes with minimal signs of hemolysis. 
Samples were processed for recovery of CTC populations 
within 96 hours using a CLIA approved process. Thirty-
two metastatic breast cancer patients were recruited. FFPE 
and blood was recovered from each donor. From the blood 
samples, germline white blood cell DNA (wbcDNA), 
ccfDNA, and ctcDNA were isolated. Sequencing libraries 
were constructed from the matched samples and subjected 
to NGS using the IonTorrent PGM platform.
Template enrichment procedures
All sample processing, sequencing and analysis was 
performed in the Cynvenio Biosystems CAP approved 
facility (Westlake Village, CA) under CLIA supervision. 
Whole blood was collected in purple top (K2EDTA) tubes 
and stabilized using LiquidBiopsy (Cynvenio Biosystems) 
fixative. A white blood cell control was recovered from 
0.1cc of the original sample. Plasma was collected after 
brief centrifugation to separate cellular components. 
CTC’s were enriched as described [25]. In brief, the 
cellular component in the starting blood volume was 
blocked with FcR block and labelled with a biotinylated 
antibody cocktail consisting of anti-EpCAM alone, or in 
combination with anti-HER2, and anti-TROP2 (Cynvenio 
Biosystems) followed by iMAG streptavidin beads. The 
labeled blood was processed in the CTC flow cell on the 
LiquidBiopsy platform (Cynvenio Biosystems). Captured 
cells were characterized by evaluating immunofluorescent 
staining with anti-Cytokeratin, anti-CD45 and DAPI. 
Captured cells were recovered by centrifugation to 
produce an enriched cell pellet. The CTC pellet was 
digested as described [25] and the resulting digest was 
diluted to 12μL with TE. The AmpliSeq library reagents 
were added directly to the template and further processed 
as for the germline and ccfDNA samples.
For enrichment of ccfDNA from the recovered 
plasma, the QIAamp Circulating Nucleic Acid Kit was 
used along with the QIAVAC system as recommended by 
the manufacturer (Qiagen, Valencia, CA). DNA resulting 
from this purification was quantitated on a Nanodrop 
(Thermo Fisher Scientific) and directly utilized for 
sequencing library generation. ccfDNA libraries were 
produced with a 10 ng input of ccfDNA.
FFPE processed slides were H&E stained, graded 
by pathologist to indicate the area of specific tumor tissue, 
macro-dissected, and placed into individual tubes. Three to 
six 5μm thick sections were processed using the Agencourt® 
FormaPure® kit (Beckman Coulter). Samples were eluted 
in 45μL and DNA was concentrated further with Agencourt 
AMPure XP beads to yield a final DNA volume of 15μL. 
DNA concentration was measured by Qubit® dsDNA HS 
(High Sensitivity) Assay Kit (Thermo Fisher Scientific).
Sequencing data analysis
Primary sequence was demultiplexed and exported 
from the Torrent Server as FASTQ. The FASTQ files were 
aligned by reference guided assembly to NCBI GRCh37 
p5 using Bowtie 2 [66]. Post-assembly alignments were 
piled and curated for accuracy using SAM Tools (version 
0.1.19) [67] and transferred to Perl using Bio::DB::Sam. 
ctcDNA and ccfDNA templates were analyzed and a 
mutation was called if ≥20 mutant reads were observed for 
a limit of detection (LOD) of 1%. FFPE templates were 
analyzed to a LOD of 10%. ctcDNA and ccfDNA analysis 
was based upon a case-control model for variant detection, 
in which total read coverage must be ≥ 2000 reads per 
amplicon for ctcDNA and ccfDNA sample and validated 
calls were required to be absent from the negative control 
wbcDNA sequence (Supplementary Figure S1). FFPE 
analysis was not case-controlled, and total read coverage 
threshold was ≥ 500 reads per amplicon.
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